Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00388349 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
A Phase 2 study of Lymphoma and Hodgkin Disease, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 146
- Enrollment target
- 1
- Study location
NCT00388349: Completed Phase 2 study of Lymphoma and Hodgkin Disease, sponsored by Stanford University.
NCT00388349 is a Phase 2 study of Lymphoma and Hodgkin Disease that has completed, run by Stanford University. The registered enrollment target is 146 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00388349, a Phase 2 study of Lymphoma and Hodgkin Disease, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 146 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 2 study of gemcitabine + high-dose chemotherapy followed by peripheral blood stem cell (PBSC) rescue for Hodgkin's Disease
Primary Outcome
Reported as the number of Phase 1 participants by gemcitabine dose that experienced non-hematologic toxicity, ie, drug-related adverse events.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Etoposide
- DRUG Gemcitabine
- DRUG Carmustine
- DRUG Vinorelbine
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2001-09 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
What the finished NCT00388349 record still lists
NCT00388349 is an interventional study that assigns participants to a tested intervention. The registered 146 participants enrollment target is mid-sized for trials with a published cap, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (70% lower).
The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00388349 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00388349 about?
NCT00388349 is a clinical study titled "Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease". This is a phase 2 study of gemcitabine + high-dose chemotherapy followed by peripheral blood stem cell (PBSC) rescue for Hodgkin's Disease
What is the current status of trial NCT00388349?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 146 participants. The study started on 2001-09. Estimated completion is 2010-09.
What conditions does trial NCT00388349 study?
This clinical trial studies the following conditions: Lymphoma, Hodgkin Disease, Hodgkin's Lymphoma.
What interventions are being tested in trial NCT00388349?
The interventions under investigation include: Cyclophosphamide (DRUG), Etoposide (DRUG), Gemcitabine (DRUG), Carmustine (DRUG), Vinorelbine (DRUG).
Who is sponsoring clinical trial NCT00388349?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00388349 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00388349's enrollment target sits among peer trials
146 62nd of 299 higher than 238 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03490929 · 146 participants · Phase 4
CEUS for Blunt Abdominal Trauma in Children
- NCT04755062 · 146 participants · NA
A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans
- NCT04867954 · 146 participants
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
- NCT05051618 · 146 participants · NA
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia